← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS › Vinca alkaloids and analogues
vintafolide
L01CA06
Forms & Strengths
- Vintafolide is a folate-targeted agent
- Supplied as a sterile, non-pyrogenic, lyophilized powder for injection
- Available in 10ml vials containing 3mg of vintafolide
Adult Dosing
- Recommended dose: 2.5mg/m² given as an intravenous injection over 5-10 minutes
- Dosage regimen: every 7 days (in combination with pegylated liposomal doxorubicin) for 6 cycles, then every 14 days as a single agent until disease progression or unacceptable toxicity
Pediatric Dosing
- Not established for pediatric use
- No data are available for patients under 18 years of age
Indications
- Treatment of adult patients with platinum-resistant ovarian cancer
- Used in combination with pegylated liposomal doxorubicin
Mechanism of Action
- Folate receptor-mediated endocytosis of the cytotoxic vinca alkaloid desacetylvinblastine hydrazide (DAVLBH)
- Selective delivery of the potent microtubule inhibitor DAVLBH to cancer cells overexpressing the folate receptor
- Induces microtubule depolymerization, leading to cell cycle arrest and apoptosis
Contraindications
- Hypersensitivity to vintafolide, other vinca alkaloids, or to any of its excipients
- Severe hepatic impairment (Child-Pugh C)
Adverse Reactions
- Common adverse reactions: neutropenia, lymphopenia, thrombocytopenia, mucositis, fatigue, nausea, diarrhea
- Serious adverse reactions: febrile neutropenia, infection, peripheral neuropathy, hypersensitivity reactions
Drug Interactions
- Vintafolide may interact with other myelosuppressive or hepatotoxic agents, increasing the risk of adverse effects
- P-glycoprotein inhibitors may increase the exposure of vintafolide and its metabolites, potentially leading to increased toxicity
Curated Content: Needs Vetting Before Put to Clinical Use